DE69734778T2 - Polynukleotid-impfstoffformulierung gegen pferdekrankheiten - Google Patents

Polynukleotid-impfstoffformulierung gegen pferdekrankheiten Download PDF

Info

Publication number
DE69734778T2
DE69734778T2 DE69734778T DE69734778T DE69734778T2 DE 69734778 T2 DE69734778 T2 DE 69734778T2 DE 69734778 T DE69734778 T DE 69734778T DE 69734778 T DE69734778 T DE 69734778T DE 69734778 T2 DE69734778 T2 DE 69734778T2
Authority
DE
Germany
Prior art keywords
plasmid
vaccine
gene
ehv
virus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69734778T
Other languages
German (de)
English (en)
Other versions
DE69734778D1 (de
Inventor
Jean-Christophe Audonnet
Annabelle Bouchardon
Michel Riviere
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim Animal Health France SAS
Boehringer Ingelheim Animal Health USA Inc
Original Assignee
Merial SAS
Merial Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merial SAS, Merial Inc filed Critical Merial SAS
Application granted granted Critical
Publication of DE69734778D1 publication Critical patent/DE69734778D1/de
Publication of DE69734778T2 publication Critical patent/DE69734778T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/205—Rhabdoviridae, e.g. rabies virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A61K39/27—Equine rhinopneumonitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16722—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16734—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20111—Lyssavirus, e.g. rabies virus
    • C12N2760/20122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20111—Lyssavirus, e.g. rabies virus
    • C12N2760/20134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE69734778T 1996-07-19 1997-07-15 Polynukleotid-impfstoffformulierung gegen pferdekrankheiten Expired - Lifetime DE69734778T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR9609400A FR2751226B1 (fr) 1996-07-19 1996-07-19 Formule de vaccin polynucleotidique contre les pathologies du cheval
FR9609400 1996-07-19
PCT/FR1997/001314 WO1998003198A1 (fr) 1996-07-19 1997-07-15 Formule de vaccin polynucleotidique contre les pathologies du cheval

Publications (2)

Publication Number Publication Date
DE69734778D1 DE69734778D1 (de) 2006-01-05
DE69734778T2 true DE69734778T2 (de) 2006-09-07

Family

ID=9494494

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69734778T Expired - Lifetime DE69734778T2 (de) 1996-07-19 1997-07-15 Polynukleotid-impfstoffformulierung gegen pferdekrankheiten

Country Status (13)

Country Link
US (2) US6207166B1 (enExample)
EP (2) EP1647281A3 (enExample)
JP (2) JP2000516199A (enExample)
AR (2) AR009947A1 (enExample)
AU (1) AU735372B2 (enExample)
BR (1) BR9710502A (enExample)
CA (2) CA2660355C (enExample)
CZ (2) CZ300593B6 (enExample)
DE (1) DE69734778T2 (enExample)
FR (1) FR2751226B1 (enExample)
NZ (1) NZ333754A (enExample)
PL (1) PL188409B1 (enExample)
WO (1) WO1998003198A1 (enExample)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2751226B1 (fr) * 1996-07-19 1998-11-27 Rhone Merieux Formule de vaccin polynucleotidique contre les pathologies du cheval
FR2775601B1 (fr) 1998-03-03 2001-09-21 Merial Sas Vaccins vivants recombines et adjuves
FR2776928B1 (fr) * 1998-04-03 2000-06-23 Merial Sas Vaccins adn adjuves
FR2794648B1 (fr) * 1999-06-10 2003-03-07 Merial Sas Vaccins adn pour animaux de compagnie et de sport
EP1185662B1 (fr) * 1999-06-10 2011-03-02 Merial Vaccins adn pour les chiens
US6645740B1 (en) * 1999-06-10 2003-11-11 Merial Limited Nucleic acids encodings equine GM-CSF
WO2001083528A2 (en) * 2000-05-01 2001-11-08 Powderject Vaccines, Inc. Nucleic acid immunization
US6803041B2 (en) * 2001-03-20 2004-10-12 Boehringer Ingelheim Vetmedica, Inc. Equine herpesvirus vaccine
FR2823222B1 (fr) 2001-04-06 2004-02-06 Merial Sas Vaccin contre le virus de la fievre du nil
US7906311B2 (en) 2002-03-20 2011-03-15 Merial Limited Cotton rat lung cells for virus culture
EP2390352A1 (en) 2003-03-18 2011-11-30 Quantum Genetics Ireland Limited Systems and methods for improving protein and milk production of dairy herds
US7468273B2 (en) 2003-05-01 2008-12-23 Meial Limited Canine GHRH gene, polypeptides and methods of use
ES2417019T3 (es) 2003-11-13 2013-08-05 University Of Georgia Research Foundation, Inc. Procedimiento de caracterización del virus de la enfermedad de la bursitis infecciosa
JP2007525217A (ja) 2004-02-19 2007-09-06 ザ ガバナーズ オブ ザ ユニバーシティー オブ アルバータ レプチンプロモーター多型及びその使用
US7959929B2 (en) 2005-04-21 2011-06-14 University Of Florida Research Foundation, Inc. Materials and methods for respiratory disease control in canines
US11865172B2 (en) 2005-04-21 2024-01-09 University Of Florida Research Foundation, Inc. Materials and methods for respiratory disease control in canines
US7803612B2 (en) 2005-04-25 2010-09-28 Merial Limited Nipah virus vaccines
US20080241184A1 (en) 2005-08-25 2008-10-02 Jules Maarten Minke Canine influenza vaccines
EP2186823A1 (en) 2005-11-14 2010-05-19 Merial Limited Gene therapy for renal failure
US7771995B2 (en) 2005-11-14 2010-08-10 Merial Limited Plasmid encoding human BMP-7
US7682619B2 (en) 2006-04-06 2010-03-23 Cornell Research Foundation, Inc. Canine influenza virus
US7862821B2 (en) 2006-06-01 2011-01-04 Merial Limited Recombinant vaccine against bluetongue virus
AU2007352618B2 (en) 2007-05-02 2013-07-18 Boehringer Ingelheim Animal Health USA Inc. DNA plasmids having improved expression and stability
US20080274137A1 (en) * 2007-05-02 2008-11-06 Jean Christophe Francis Audonnet DNA plasmids having improved expression and stability
EP2367566B2 (en) 2008-11-28 2019-11-27 Boehringer Ingelheim Animal Health USA Inc. Recombinant avian influenza vaccine and uses thereof
EP2414386B1 (en) 2009-04-03 2016-01-27 Merial Limited Newcastle disease virus vectored avian vaccines
CA2785653C (en) 2009-12-28 2018-05-01 Merial Limited Recombinant ndv antigen and uses thereof
US20130197612A1 (en) 2010-02-26 2013-08-01 Jack W. Lasersohn Electromagnetic Radiation Therapy
CA2792117C (en) 2010-03-12 2016-09-20 Merial Limited Foot and mouth disease virus recombinant vaccines and uses thereof
CA2809127C (en) 2010-08-31 2019-04-02 Merial Limited Newcastle disease virus vectored herpesvirus vaccines
WO2012090073A2 (en) 2010-12-30 2012-07-05 The Netherlands Cancer Institute Methods and compositions for predicting chemotherapy sensitivity
US20140296248A1 (en) 2011-04-04 2014-10-02 Stichting het Nederlands Kanker Instiuut-Antoni van Leeuwenhoek ziekenhuis Methods and compositions for predicting resistance to anticancer treatment
WO2012138789A2 (en) 2011-04-04 2012-10-11 Netherlands Cancer Institute Methods and compositions for predicting resistance to anticancer treatment
WO2012145577A1 (en) 2011-04-20 2012-10-26 Merial Limited Adjuvanted rabies vaccine with improved viscosity profile
HK1200329A1 (en) 2011-04-25 2015-08-07 先进生物学实验室股份有限公司 Truncated hiv envelope proteins (env), methods and compositions related thereto
WO2012166450A1 (en) 2011-05-27 2012-12-06 Merial Limited Genetic vaccines against hendra virus and nipah virus
EP2714077B1 (en) 2011-06-01 2018-02-28 Merial, Inc. Needle-free administration of prrsv vaccines
HUE035774T2 (en) 2011-08-12 2018-05-28 Merial Inc Biological substances, in particular vaccines, preserved by vacuum
WO2013093629A2 (en) 2011-12-20 2013-06-27 Netherlands Cancer Institute Modular vaccines, methods and compositions related thereto
EA032389B1 (ru) 2012-02-14 2019-05-31 Мериал, Инк. Рекомбинантные поксвирусные векторы, кодирующие и экспрессирующие гликопротеин g вируса бешенства и полипептид oxl, и вакцины, созданные на их основе, используемые в способе вакцинации животных против бешенства
PL2814508T3 (pl) 2012-02-14 2017-09-29 Merial, Inc. Szczepionki podjednostkowe przeciw rotawirusom oraz sposoby ich wytwarzania i zastosowania
WO2013138776A1 (en) 2012-03-16 2013-09-19 Merial Limited Novel methods for providing long-term protective immunity against rabies in animals, based upon administration of replication-deficient flavivirus expressing rabies g
KR101490292B1 (ko) 2012-04-16 2015-02-04 한국생명공학연구원 신규한 ｈ3ｎ8 말 인플루엔자 바이러스
MA37749B1 (fr) 2012-06-13 2017-05-31 Merial Ltd Vaccins contre les virus réassortis de la fièvre catarrhale et de la peste équine
US9556419B2 (en) 2013-03-12 2017-01-31 Merial Inc. Reverse genetics Schmallenberg virus vaccine compositions, and methods of use thereof
AU2015343369B2 (en) 2014-11-03 2018-11-22 Georgia Tech Research Corporation Methods of using microneedle vaccine formulations to elicit in animals protective immunity against rabies virus
EP3738975A1 (en) 2015-06-23 2020-11-18 Boehringer Ingelheim Animal Health USA Inc. Prrsv minor protein-containing recombinant viral vectors and methods of making and use thereof
EP3337503A1 (en) 2015-08-20 2018-06-27 Merial, Inc. Fcv recombinant vaccines and uses thereof
CN108348594B (zh) 2015-09-29 2022-09-09 勃林格殷格翰动物保健美国公司 犬科动物细小病毒(cpv)病毒样颗粒(vlp)疫苗及其用途
ES2899230T3 (es) 2015-11-23 2022-03-10 Boehringer Ingelheim Animal Health Usa Inc Proteínas de fusión de FMDV y E2 y usos de las mismas
TWI760322B (zh) 2016-01-29 2022-04-11 美商百靈佳殷格翰動物保健美國有限公司 重組腺病毒載體裝載之fmdv疫苗及其用途
CN109136264B (zh) * 2018-09-19 2022-07-29 天康制药(苏州)有限公司 马疱疹病毒1型gB-gD融合蛋白、重组载体和真核细胞株及其制备方法和疫苗

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4631191A (en) * 1985-06-20 1986-12-23 Biotechnology Research Partners, Ltd. Methods and compositions useful in preventing equine influenza
US4944942A (en) * 1987-08-27 1990-07-31 Mobay Corporation Intranasal vaccination of horses with inactivated microorganisms or antigenic material
SU1671688A1 (ru) * 1989-01-27 1991-08-23 Всесоюзный Научно-Исследовательский Институт Молекулярной Биологии Штамм гибридных культивируемых клеток животных MUS мUSсULUS L. - продуцент моноклональных антител к гликопротеиду Е1 вируса восточного энцефаломиелита лошадей
US5185440A (en) * 1989-06-20 1993-02-09 North Carolina State University cDNA clone coding for Venezuelan equine encephalitis virus and attenuating mutations thereof
FR2659349B1 (fr) * 1990-03-12 1993-12-24 Rhone Merieux Virus herpes recombinants notamment pour la realisation de vaccins, leur procede de preparation, les plasmides realises au cours de ce procede et les vaccins obtenus.
US5643578A (en) * 1992-03-23 1997-07-01 University Of Massachusetts Medical Center Immunization by inoculation of DNA transcription unit
US5243121A (en) 1992-03-19 1993-09-07 Engelhard Corporation Fluid catalytic cracking process for increased formation of isobutylene and isoamylenes
US5925358A (en) * 1993-02-26 1999-07-20 Syntro Corporation Recombinant fowlpox viruses and uses thereof
EP0740704A1 (en) * 1994-01-27 1996-11-06 University Of Massachusetts Medical Center Immunization by inoculation of dna transcription unit
FR2751226B1 (fr) * 1996-07-19 1998-11-27 Rhone Merieux Formule de vaccin polynucleotidique contre les pathologies du cheval
WO1999050292A1 (en) * 1998-03-27 1999-10-07 The Secretary Of State For Defence Recombinant virus

Also Published As

Publication number Publication date
EP1647281A3 (fr) 2009-08-05
CA2260858C (en) 2011-01-18
US6207166B1 (en) 2001-03-27
CA2660355A1 (en) 1998-01-29
AU3772797A (en) 1998-02-10
FR2751226B1 (fr) 1998-11-27
CA2660355C (en) 2012-05-22
CZ17499A3 (cs) 1999-05-12
PL188409B1 (pl) 2005-01-31
NZ333754A (en) 2001-03-30
BR9710502A (pt) 1999-08-17
EP1647281A2 (fr) 2006-04-19
CA2260858A1 (en) 1998-01-29
CZ301365B6 (cs) 2010-01-27
CZ300593B6 (cs) 2009-06-24
PL331202A1 (en) 1999-07-05
WO1998003198A1 (fr) 1998-01-29
US6558674B1 (en) 2003-05-06
AR009947A1 (es) 2000-05-17
AU735372B2 (en) 2001-07-05
EP0936922A1 (fr) 1999-08-25
FR2751226A1 (fr) 1998-01-23
EP0936922B1 (fr) 2005-11-30
DE69734778D1 (de) 2006-01-05
JP2008143900A (ja) 2008-06-26
JP2000516199A (ja) 2000-12-05
AR059828A2 (es) 2008-04-30

Similar Documents

Publication Publication Date Title
DE69734778T2 (de) Polynukleotid-impfstoffformulierung gegen pferdekrankheiten
DE69731309T3 (de) Impfstofformel auf polynukleotidbasis zur behandlung von hundekrankheiten, insbesondere solcher des atmungs- und verdauungstraktes
DE69730839T2 (de) Hühner polynukleotide impfstoff-formulierung
DE69734483T2 (de) Polynukleotid-Impfstoff, vorzugsweise zur Behandlung der Atemkrankheit bei Rindern
DE69734284T2 (de) Zusammensetzung eines polynukleotidvakzins zur behandlung von atemwegs- und fortpflanzungsbezogenen erkrankungen des schweins
DE69736185T2 (de) Zusammensetzung eines polynucleotid-impfstoffes für katzen
DE69532068T2 (de) Rekombinanter lebender Vogel-Impfstoff, der ein Truthahn-Herpesvirus Vektor gebraucht
DE69715879T2 (de) Intradermaler polynukleotid-impfstoff aus rind
DE69923434T2 (de) Adjuvierte rekombinante Lebendimpfstoffe gegen Influenza- oder Herpesviren
AT408549B (de) Virushältiger impfstoff, rekombinantes virus und verfahren zum exprimieren eines genproduktes
AT405184B (de) Rekombinantes pockenvirus
DE3878468T2 (de) Chimarenglykoproteine, enthaltend immunogene segmente des humanen respiratorischen synzytialvirus.
DE69737231T2 (de) Impfung mit nukleinsäuren gegen parvovirus infektionen
DE69533305T2 (de) Lebende rekombinante Vogelvakzine auf eines Vogelherpesvirus gegründet, gegen Gumborokrankheit
DE69935136T2 (de) DNS Pferdeimpfstoffe adjuviert mit Acryl- oder Methacrylpolymersäuren oder EMA (R)
DE69534993T2 (de) Impfstoff aus abgeschwächten hundeparvoviren
DE69333751T2 (de) Nicht-verbreitendes lebendes herpesvirusvakzin
DE69233270T2 (de) Subeinheits-Impfstoff gegen Hundecoronavirus
DE69123970T2 (de) Ehv-4 glykoprotein vazin
DE69929530T2 (de) Attenuierter pferdeherpesvirus
DE69332264T2 (de) Mutanten des infektiösen rinder rhinotracheitis-virus und impfstoffe
DE69435081T2 (de) Rekombinanter adenovirusvektor für geflügel
DE69328341T2 (de) Impfstoff gegen infektiöse Bursal-Krankheit
DE69935445T2 (de) Attenuierte stabile tollwutvirusmutante und lebende impfstoffe
DE69332480T2 (de) Impfstoff-vektoren von rekombinantem katzen-herpesvirus

Legal Events

Date Code Title Description
8364 No opposition during term of opposition